JFNCX Performance — Janus Henderson Global Life Sciences Fund, Class C
Data updated: 2026-08-26
JFNCX returned +8.11% year to date and +38.20% over one year to Jun 2026. Annualised returns are +12.42% over 3 years and +7.54% over 5 years. The fund beat its Global Health Care Equity category average: $100 invested three years ago grew to $142, against $130 for the category, and to $138 over one year, against $124. Volatility over the past three years was 15.69% a year. In the 12 months to Jun 2026 the fund lost a net $20.5M, and assets reached $5.81B.
JFNCX Growth of $100
What $100 invested in Janus Henderson Global Life Sciences Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Global Health Care Equity category average over the same months.
| Period | JFNCX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $138 | $124 |
| 3 years (Jul 2023 – Jun 2026) | $142 | $130 |
| 5 years (Jul 2021 – Jun 2026) | $144 | $104 |
| Since data start (Jul 2019 – Jun 2026) | $220 | $160 |
JFNCX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +8.11% |
| 1 year | +38.20% |
| 3 years (annualised) | +12.42% |
| 5 years (annualised) | +7.54% |
JFNCX Annual Returns
Calendar-year total returns of Janus Henderson Global Life Sciences Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +8.11% |
| 2025 | +23.68% |
| 2024 | +2.65% |
| 2023 | +6.48% |
| 2022 | −3.53% |
| 2021 | +5.88% |
| 2020 | +24.45% |
| 2019 (Jul–Dec) | +18.50% |
JFNCX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.7% | +2.0% | −6.5% | +1.8% | +2.3% | +8.1% | — | — | — | — | — | — |
| 2025 | +5.9% | −0.3% | −4.5% | −0.4% | −5.8% | +2.3% | −0.9% | +6.0% | +2.8% | +8.6% | +9.2% | −0.2% |
| 2024 | +1.7% | +3.8% | +2.7% | −4.7% | +3.5% | +3.1% | +2.6% | +5.1% | −2.5% | −3.4% | −0.8% | −7.6% |
| 2023 | +2.6% | −4.4% | +0.4% | +2.9% | −2.4% | +4.0% | −3.8% | −1.5% | +0.9% | +7.5% | +7.3% | −6.2% |
| 2022 | +3.5% | +0.5% | −9.1% | −0.8% | −1.0% | −6.8% | −3.0% | −2.6% | +3.6% | −0.9% | +5.9% | +8.5% |
| 2021 | −2.0% | 0.0% | −0.9% | +3.5% | +0.2% | +3.0% | −4.2% | +3.1% | +0.1% | +6.7% | −7.4% | +4.4% |
| 2020 | −6.0% | −5.6% | −2.9% | +2.1% | +5.1% | +12.5% | −0.8% | +3.6% | +2.1% | +4.9% | +10.9% | −2.1% |
| 2019 | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | +4.0% | +8.3% | +5.2% |
JFNCX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 15.69%
- 3-year Sharpe ratio: 0.50 (vs 4.5% risk-free rate)
- Best month: +9.21% (Nov 2025)
- Worst month: −7.58% (Dec 2024)
JFNCX Fund Flows
Monthly money in and out of Janus Henderson Global Life Sciences Fund, from SEC Form N-PORT.
- 12-month net flow: −$20.5M
- 12-month gross sales (incl. reinvestments): $1.0B
- Sales ÷ redemptions: 0.98×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $58.5M | $85.1M | −$26.6M |
| May 2026 | $63.8M | $75.7M | −$11.9M |
| Apr 2026 | $71.3M | $83.5M | −$12.2M |
| Mar 2026 | $87.3M | $74.8M | $12.5M |
| Feb 2026 | $100.9M | $67.6M | $33.3M |
| Jan 2026 | $81.3M | $87.7M | −$6.4M |
| Dec 2025 | $316.4M | $107.9M | $208.5M |
| Nov 2025 | $63.4M | $78.4M | −$15.1M |
| Oct 2025 | $58.2M | $79.0M | −$20.8M |
| Sep 2025 | $41.6M | $82.3M | −$40.7M |
| Aug 2025 | $51.5M | $112.5M | −$60.9M |
| Jul 2025 | $39.3M | $119.4M | −$80.1M |
JFNCX Assets Under Management
Net assets of Janus Henderson Global Life Sciences Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $5.81B |
| 2026-03-31 | $5.20B |
| 2025-12-31 | $5.36B |
| 2025-09-30 | $4.57B |
| 2025-06-30 | $4.40B |
| 2025-03-31 | $4.71B |
| 2024-12-31 | $4.78B |
| 2024-09-30 | $5.73B |
| 2024-06-30 | $5.47B |
| 2024-03-31 | $5.37B |
| 2023-12-31 | $4.90B |
| 2023-09-30 | $4.58B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.